Hereditary Amyloidosis Market is segmented By Drug Type (RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotides, Transthyretin (TTR) Stabilizers), By Route of A ....
Market Size in USD
CAGR11.8%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 11.8% |
Market Concentration | High |
Major Players | Alnylam Pharmaceuticals, Pfizer Inc., Ionis Pharmaceuticals, Akcea Therapeutics, Prothena Corporation |
The hereditary amyloidosis market is estimated to be valued at USD 1.23 Bn in 2024 and is expected to reach USD 2.7 Bn by 2031, growing at a compound annual growth rate (CAGR) of 11.8% from 2024 to 2031. The increasing prevalence of hereditary amyloidosis around the world along with growing awareness regarding the disease and its treatment options among the patients are fueling the market growth.